Uncategorized
RIBOMIC Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting
TOKYO--(BUSINESS WIRE)--RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the presentation of preliminary interim results from the ongoing two Phase 2 studies, TOFU and the RAMEN extension study in patients with Wet Age-Related Macular Degeneration (wAMD) by Dr. Raj Maturi at the 54th Annual Scientific Meeting of the Retina Society, Chicago, USA. TOFU study is a double-masked, randomized, active-controlled Phase 2 trial eva